Organisation paid for research Program year 2025 Source: CMS Open Payments

Nextstage Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,252,229

162 payments

Through program year 2025, Nextstage Clinical Research is reported as receiving $2,252,229 in research payments, across 162 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $577,496 7
2024 Research $122,860 4
2022 Research $1,551,873 151

Breakdown

Who paid Research payments · program years 2022–2025
  1. Heron Therapeutics, Inc. $1,551,873 151 payments
  2. AstraZeneca Pharmaceuticals LP $700,356 11 payments
Studies the money was for Research payments · program years 2022–2025
  1. HTX-011 in Spinal Surgery $1,119,252 129 payments
  2. A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE $432,621 22 payments
  3. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity $415,851 2 payments
  4. a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $122,543 2 payments
  5. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity $96,444 2 payments
  6. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) $33,618 3 payments
  7. A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) $15,950 1 payment
  8. A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus $15,950 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record